From the Alabama College of Osteopathic Medicine, Montgomery, Alabama.
Aimmune Therapeutics, a Nestle Health Science company, Brisbane, California.
Allergy Asthma Proc. 2021 Jul 1;42(4):333-342. doi: 10.2500/aap.2021.42.210047.
Until recently, the standard approach to care for individuals with peanut allergy (PA) was limited to allergen avoidance and treatment of reactions with emergency medicines. To assess health-care resource utilization (HRU) and costs associated with PA management under allergen avoidance and to identify risk factors associated with peanut reactions that resulted in inpatient (IP) and/or emergency department (ED) visits. Privately insured individuals with PA diagnosis codes were identified from a large U.S. administrative claims data base (January 1, 1999, to March 31, 2017). PA-related HRU, indicated by a PA diagnosis and/or diagnostic procedure codes and by epinephrine autoinjectors (EAI) prescription fills in medical and pharmacy claims, respectively, and all-cause costs were described per patient-year (PPY). Risk factors associated with peanut reactions in an IP and/or ED setting were identified by using a multivariable logistic regression model. A total of 86,483 patient-years from 14,136 individuals with PA were included. At the patient-year level, 28.1% were ages 0-3 years, 43.6% were ages 4-11 years, 13.7% were ages 12-17 years, and 14.5% were ages ≥ 18 years; 35.6% had PA-related outpatient visits; 50.6% had EAI fills; and 2.4% had PA-related IP and/or ED visits PPY. Younger individuals had more PA-related outpatient visits and EAI fills, with peak intensive use at ages 4-11 years. The proportion of individuals with PA-related IP and/or ED visits was highest among those aged ≥ 18 years. Mean all-cause costs were $3084 PPY; individuals with PA-related IP and/or ED visits incurred $8902 PPY ($17,451 for those with one or more IP visits). Risk factors associated with peanut reactions that resulted in IP and/or ED visits included young adults (odds ratio [OR] 3.19 [95% confidence interval {CI}, 2.66-3.83]), previous peanut reaction(s) (OR 1.66 [95% CI, 1.23-2.24]), asthma (OR 1.33 [95% CI, 1.18-1.51]), and male sex (OR 1.14 [95% CI, 1.01-1.28]). Individuals with PA and under allergen avoidance had significant HRU that varied across all age groups, with more PA-related outpatient visits during preschool and/or school age and PA-related urgent care among adults. Individuals with previous peanut reaction(s), asthma, and males had a higher risk of peanut reactions that resulted in IP and/or ED visits.
直到最近,对花生过敏(PA)患者的标准治疗方法仅限于过敏原回避和使用急救药物治疗反应。评估过敏原回避下 PA 管理相关的医疗资源利用(HRU)和成本,并确定导致住院(IP)和/或急诊部(ED)就诊的与花生反应相关的风险因素。从一个大型美国行政索赔数据库(1999 年 1 月 1 日至 2017 年 3 月 31 日)中确定了有 PA 诊断代码的私人保险个体。通过 PA 诊断和/或诊断程序代码以及医疗和药房索赔中的肾上腺素自动注射器(EAI)处方填写,分别描述了与 PA 相关的 HRU,并按每位患者-年(PPY)进行了描述。通过多变量逻辑回归模型确定了与 IP 和/或 ED 环境中花生反应相关的风险因素。共纳入 14136 例 PA 患者的 86483 个患者-年。在患者-年水平上,28.1%为 0-3 岁,43.6%为 4-11 岁,13.7%为 12-17 岁,14.5%为 18 岁及以上;35.6%有 PA 相关的门诊就诊;50.6%有 EAI 填充;2.4%有 PA 相关的 IP 和/或 ED 就诊 PPY。年龄较小的个体有更多的 PA 相关门诊就诊和 EAI 填充,在 4-11 岁时达到密集使用的高峰。≥18 岁人群中 PA 相关 IP 和/或 ED 就诊的比例最高。平均全因成本为 3084 美元 PPY;有 PA 相关 IP 和/或 ED 就诊的患者 PPY 花费 8902 美元(有一次或多次 IP 就诊的患者花费 17451 美元)。导致 IP 和/或 ED 就诊的花生反应的相关风险因素包括年轻人(比值比[OR]3.19[95%置信区间{CI},2.66-3.83])、以前的花生反应(OR 1.66[95%CI,1.23-2.24])、哮喘(OR 1.33[95%CI,1.18-1.51])和男性(OR 1.14[95%CI,1.01-1.28])。在过敏原回避下,有 PA 的个体有显著的 HRU,在所有年龄组中都有差异,学龄前和/或上学期间有更多的 PA 相关门诊就诊,成人中有更多的 PA 相关紧急护理。有既往花生反应、哮喘和男性的个体发生导致 IP 和/或 ED 就诊的花生反应的风险更高。